SGFEF Stock Chart & Stats
$104.61
$0.00(0.00%)
At close: 4:00 PM EDT
$104.61
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$84.12 - $114.35
Previous CloseN/A
Volume80.00
Average Volume (3M)0.00
Market Cap
$4.05B
Enterprise Value$3.41B
Total Cash (Recent Filing)$103.80M
Total Debt (Recent Filing)$575.20M
Price to Earnings (P/E)18.7
Beta0.22
Next Earnings
Aug 21, 2026EPS Estimate
1.98Next Dividend Ex-DateN/A
Dividend Yield0.47%
Share Statistics
EPS (TTM)3.85
Shares Outstanding45,230,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio5.13
Price to Book (P/B)2.89
Price to Sales (P/S)2.46
P/FCF Ratio327.33
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue2.57
Enterprise Value/Gross Profit9.63
Enterprise Value/Ebitda11.24
Forecast
1Y Price Target
$111.74Price Target Upside6.82% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)4.99
Revenue Forecast (FY)$1.74B
Bulls Say, Bears Say
Bulls Say
Financial HealthSFZN's balance sheet is seen as healthy, which supports potential US expansion and merger or acquisition activities.
Market PositionSFZN is positioned to outperform peers due to its strong position in the generics market, especially against competitors facing higher tariffs.
Operational EfficiencyEBITDA margins are anticipated to increase, reflecting a positive outlook on operational efficiency.
Bears Say
Growth ExpectationsThe margin guide leads to limited margin expansion potential for FY25, with scope for negative revisions in the near term.
Near-term PressureThe company is expected to face near-term pressure with limited catalysts for stock improvement in the first half of the year.
Profit MarginsAnalyst notes that generics are hit harder by tariffs compared to exclusive contracts, potentially impacting profit margins.
Siegfried Holding AG News
SGFEF FAQ
What was Siegfried Holding AG’s price range in the past 12 months?
Siegfried Holding AG lowest stock price was $84.12 and its highest was $114.35 in the past 12 months.
What is Siegfried Holding AG’s market cap?
Siegfried Holding AG’s market cap is $4.05B.
When is Siegfried Holding AG’s upcoming earnings report date?
Siegfried Holding AG’s upcoming earnings report date is Aug 21, 2026 which is in 47 days.
How were Siegfried Holding AG’s earnings last quarter?
Siegfried Holding AG released its earnings results on Feb 20, 2026. The company reported $2.747 earnings per share for the quarter, beating the consensus estimate of $2.705 by $0.041.
Is Siegfried Holding AG overvalued?
According to Wall Street analysts Siegfried Holding AG’s price is currently Undervalued.
Does Siegfried Holding AG pay dividends?
Siegfried Holding AG pays a Annually dividend of $0.507 which represents an annual dividend yield of 0.47%. See more information on Siegfried Holding AG dividends here
What is Siegfried Holding AG’s EPS estimate?
Siegfried Holding AG’s EPS estimate is 1.98.
How many shares outstanding does Siegfried Holding AG have?
Siegfried Holding AG has 45,230,000 shares outstanding.
What happened to Siegfried Holding AG’s price movement after its last earnings report?
Siegfried Holding AG reported an EPS of $2.747 in its last earnings report, beating expectations of $2.705. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Siegfried Holding AG?
Currently, no hedge funds are holding shares in SGFEF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Siegfried Holding AG
Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. It offers drug substances, including exclusive synthesis that manufactures custom APIs. The company also offers an API portfolio, including non-exclusive APIs and pharma-grade substances that focus on anesthetics, pain and addiction treatment applications, and central nervous and respiratory diseases, as well as caffeine for human health and nutrition. In addition, it offers drug products, including steriles, which includes fill and finish in vials, ampoules, cartridges, and pre-filled syringes; ophthalmics, such as sterile ointments, gels, and suspensions and solutions; inhalation products, including capsules in medical devices for inhalation applications; oral solid dosage forms, which includes tablets and capsules; and viral vectors, such as AAV and lentiviruses for gene therapy. Further, the company provides technologies with chemistry capabilities, analytical services, formulation technologies, bridging technologies, containment technology, and cell and gene therapies. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.
SGFEF Company Deck
SGFEF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely positive operational and financial picture: record profitability, margin expansion to ~23.5%, strong cash generation, major strategic investments and an accretive U.S. acquisition that strengthens the network. Management also highlighted robust commercial momentum (RFP wins +30%), quality and safety improvements, and concrete sustainability progress. Key risks discussed were a material pending confirmation on one large on‑market Drug Substance product (creating cautious Drug Substance guidance for 2026), meaningful currency headwinds, and near‑term top‑line timing/seasonality and elevated investment-related ramp timing. On balance, the strengths — sustainable margin improvement, cash and balance sheet flexibility, M&A that increases strategic optionality, and clear commercial momentum — outweigh the near‑term uncertainties.View all SGFEF earnings summariesSGFEF Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$111.74
▲(6.82% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Lonza Group Ltd
―
Bachem Holding AG
―
PolyPeptide Group AG
―
Sandoz Group Ltd
―
Galenica AG
―
Ownership Overview
―
Insiders
8.52% Mutual Funds
― Other Institutional Investors
83.89% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---









